MX2024001417A - Compuestos de heteroarilo para tratar la enfermedad de huntington. - Google Patents

Compuestos de heteroarilo para tratar la enfermedad de huntington.

Info

Publication number
MX2024001417A
MX2024001417A MX2024001417A MX2024001417A MX2024001417A MX 2024001417 A MX2024001417 A MX 2024001417A MX 2024001417 A MX2024001417 A MX 2024001417A MX 2024001417 A MX2024001417 A MX 2024001417A MX 2024001417 A MX2024001417 A MX 2024001417A
Authority
MX
Mexico
Prior art keywords
disease
compounds
heteroaryl compounds
treating huntington
forms
Prior art date
Application number
MX2024001417A
Other languages
English (en)
Spanish (es)
Inventor
Guangming Chen
Jana Narasimhan
Nanjing Zhang
Gary Mitchell Karp
Hongyu Ren
Nadiya Sydorenko
Suresh Babu
Anuradha Bhattacharyya
Young- Choon MOON
Rauful Alam
Matthew S Eastwood
Seyedmorteza Hosseyni
Yao Jiang
Matthew G Woll
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2024001417A publication Critical patent/MX2024001417A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2024001417A 2021-07-30 2022-07-29 Compuestos de heteroarilo para tratar la enfermedad de huntington. MX2024001417A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163203761P 2021-07-30 2021-07-30
PCT/US2022/038870 WO2023009816A1 (en) 2021-07-30 2022-07-29 Heteroaryl compounds for treating huntington's disease

Publications (1)

Publication Number Publication Date
MX2024001417A true MX2024001417A (es) 2024-05-14

Family

ID=83149486

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001417A MX2024001417A (es) 2021-07-30 2022-07-29 Compuestos de heteroarilo para tratar la enfermedad de huntington.

Country Status (16)

Country Link
US (1) US20240336613A1 (cg-RX-API-DMAC7.html)
EP (1) EP4377317A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024528066A (cg-RX-API-DMAC7.html)
KR (1) KR20240054264A (cg-RX-API-DMAC7.html)
CN (1) CN118159539A (cg-RX-API-DMAC7.html)
AR (1) AR126612A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022320725A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227287A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000250A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000890A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240043A (cg-RX-API-DMAC7.html)
IL (1) IL310440A (cg-RX-API-DMAC7.html)
MX (1) MX2024001417A (cg-RX-API-DMAC7.html)
PE (1) PE20240929A1 (cg-RX-API-DMAC7.html)
TW (1) TW202321247A (cg-RX-API-DMAC7.html)
WO (1) WO2023009816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CA3249778A1 (en) * 2022-06-15 2023-12-21 Ptc Therapeutics, Inc. HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
JP2022525417A (ja) * 2019-03-15 2022-05-13 スカイホーク・セラピューティクス・インコーポレーテッド 異常スプライシングを修正するための組成物および方法

Also Published As

Publication number Publication date
CR20240043A (es) 2024-05-22
CO2024000890A2 (es) 2024-04-29
EP4377317A1 (en) 2024-06-05
JP2024528066A (ja) 2024-07-26
CL2024000250A1 (es) 2024-07-12
PE20240929A1 (es) 2024-04-30
US20240336613A1 (en) 2024-10-10
AR126612A1 (es) 2023-10-25
CA3227287A1 (en) 2023-02-02
AU2022320725A1 (en) 2024-02-22
CN118159539A (zh) 2024-06-07
IL310440A (en) 2024-03-01
WO2023009816A1 (en) 2023-02-02
TW202321247A (zh) 2023-06-01
KR20240054264A (ko) 2024-04-25

Similar Documents

Publication Publication Date Title
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
MX2020009957A (es) Compuestos para el tratamiento de enfermedad de hungtinton.
ZA202100208B (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
CR20240043A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
WO2018226622A8 (en) Compounds for treating huntington's disease
ZA202403923B (en) Heterocyclic compounds as immunomodulators
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2024014435A (es) Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington
MX2022001690A (es) Compuestos deuterados para usarse en el tratamiento del cancer.
MX2019011530A (es) Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
PH12021500034A1 (en) Compounds useful in hiv therapy
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2024002131A (es) Inhibidores de la 17-beta-hidroxisteroide deshidrogenasa tipo 13 y metodos de uso de los mismos.
SE9903894D0 (sv) Novel compounds
ZA202400821B (en) Inhibitors of transglutaminases
MX2023009166A (es) Derivados de quinoxalina y sus usos.
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.
MX2023015096A (es) Inhibidores de transglutaminasas.
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
MX2024014831A (es) Derivados de acido sialico y metodos de uso de los mismos